Quality first in obstructive hypertrophic cardiomyopathy

Affiliations

¹ Department of Cardiology, Royal Brisbane and Women's Hospital and University of Queensland Faculty of Medicine, Herston, QLD 4029, Australia; School of Medicine, Griffith University, Brisbane, QLD, Australia.
² Department of Cardiology, Royal Brisbane and Women's Hospital and University of Queensland Faculty of Medicine, Herston, QLD 4029, Australia; Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. Electronic address: john.atherton@health.qld.gov.au.

Comment

Sandhir B Prasad et al. Lancet. 2021.

. 2021 Jun 26;397(10293):2440-2441.

doi: 10.1016/S0140-6736(21)00898-9. Epub 2021 May 15.

¹ Department of Cardiology, Royal Brisbane and Women's Hospital and University of Queensland Faculty of Medicine, Herston, QLD 4029, Australia; School of Medicine, Griffith University, Brisbane, QLD, Australia.
² Department of Cardiology, Royal Brisbane and Women's Hospital and University of Queensland Faculty of Medicine, Herston, QLD 4029, Australia; Faculty of Health, Queensland University of Technology, Brisbane, QLD, Australia. Electronic address: john.atherton@health.qld.gov.au.

No abstract available

Comment on

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Spertus JA, Fine JT, Elliott P, Ho CY, Olivotto I, Saberi S, Li W, Dolan C, Reaney M, Sehnert AJ, Jacoby D. Spertus JA, et al. Lancet. 2021 Jun 26;397(10293):2467-2475. doi: 10.1016/S0140-6736(21)00763-7. Epub 2021 May 15. Lancet. 2021. PMID: 34004177 Clinical Trial.